Fate Therapeutics Inc (FATE)

[jondoeuk]

Yes. The IL7-RF to increase persistence and CD38 KO to enhance metabolic fitness and persistence. The latter also overcomes anti-CD38 mAb-mediated fratricide so allows for targeted conditioning (no cy/flu)*.

There is preclinical data from other groups https://aacrjournals.org/cancerdiscovery/article/7/11/1238/6513/Constitutive-Signaling-from-an-Engineered-IL7 https://www.cell.com/molecular-therapy-family/oncology/fulltext/S2950-3299(24)00061-4

* https://ashpublications.org/blood/article/140/Supplement%201/7388/492103/iPSC-Derived-CD38-Null-NK-Cells-in-Combination